Candesartan

7 trials 2 recruiting CCardiology

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

2 Recruiting

2 Completed trials

7 Sponsors

13 Countries

Phase III

Phase II

Phase III/IV

Phase IV

Phase III: 3 Phase II: 1 Phase III/IV: 1 Phase IV: 2

Oversight events:

9 temporary halts 1 urgent safety measure across 1 trial

View oversight register →

Indications tested

Focal segmental glomerulosclerosis 1

Sponsors using this IMP

Helse Bergen HF 2 St. Olavs Hospital HF 2 Andrea Di Marco 1 Dimerix Bioscience Pty Limited 1 Medical University Of Vienna 1 Novartis Pharma AG 1 Policlinico San Donato S.p.A. 1

All trials

7 total

Prevention of heart disease in heart-healthy patients with diabetes based on a special parameter (NT-proBNP) Pending

2024-519051-28-01 Phase IV 2 countries Medical University Of Vienna
Episodic CandClus2: A randomized, placebo-controlled, triple blind study of candesartan in adults with episodic cluster headache Pending

2025-521470-34-00 Phase III 2 countries Helse Bergen HF; St. Olavs Hospital HF
Chronic CandClus2: A randomized, placebo-controlled, triple blind crossover study of candesartan in adults with chronic cluster headache Pending

2025-521529-34-00 Phase III 2 countries Helse Bergen HF; St. Olavs Hospital HF
Pharmacological optimization in prevention in Heart Failure: A Sex-gap? Recruiting

2025-520660-18-00 Phase IV 1 country Policlinico San Donato S.p.A.
Withdrawal of neurohormonal therapy in patients with non-ischemic cardiomyopathy, no late gadolinium enhancement, and negative genetic testi… Recruiting

2025-521780-12-00 Phase III/IV 1 country Andrea Di Marco
Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis Ended

2023-504597-37-00 Phase III 7 countries Dimerix Bioscience Pty Limited
A proof of concept and dose-finding study of XXB750 in patients with heart failure Ended

2023-504678-39-00 Phase II 11 countries Novartis Pharma AG

Showing 1–7 of 7 trials

← All drugs A–Z